[{"orgOrder":0,"company":"Leo Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"STAT6","graph1":"Immunology","graph2":"Preclinical","graph3":"Leo Pharma","amount2":1.7,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":1.7,"dosageForm":"Oral","sponsorNew":"Leo Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Leo Pharma \/ Gilead Sciences"},{"orgOrder":0,"company":"ISD Immunotech","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"ISD017","moa":"STING","graph1":"Immunology","graph2":"Preclinical","graph3":"ISD Immunotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISD Immunotech \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"ISD Immunotech \/ Biogen"},{"orgOrder":0,"company":"ISD Immunotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"ISD017","moa":"STING","graph1":"Immunology","graph2":"Preclinical","graph3":"ISD Immunotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISD Immunotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ISD Immunotech \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The partnership aims to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 programs for the potential treatment of patients with inflammatory diseases.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : $250.0 million

                          January 11, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Gilead Sciences

                          Deal Size : $1,700.0 million

                          Deal Type : Partnership

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : ISD and Biogen will work together to develop ISD's lead compound, ISD 017, which is being developed to treat severe lupus - systemic lupus erythematosus (SLE).

                          Product Name : ISD017

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          November 23, 2020

                          Lead Product(s) : ISD017

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Biogen

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank